Posted by Michael Wonder on 17 Jun 2017
Ipsen announces FDA approval of Dysport (abobotulinumtoxin A) for the treatment of lower limb spasticity in adults
16 June 2017 - Ipsen today announced that the U.S. FDA has expanded the approved use of Dysport (abobotulinumtoxin A) for injection for the treatment of spasticity in adults, based on its supplemental biologics license application in lower limb spasticity.
In July 2015, Dysport was approved for the treatment of upper limb spasticity in adults. In July 2016, Dysport was approved to treat paediatric patients with lower limb spasticity aged two and older, making it the first and only botulinum toxin that the FDA approved for this indication.
